Navigation Links
National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion
Date:5/7/2009

Goal is to Enhance Patient Safety and Reduce Health Care Costs

BETHESDA, Md., May 7 /PRNewswire-USNewswire/ -- Beginning today, nine hospitals will join in a pilot program, contributing data on adverse events associated with blood transfusions. By analyzing the data collected, it will be possible to identify best practices that can be implemented to significantly improve patient safety while reducing overall costs to the health care system.

This pilot hemovigilance program is one of four components comprising the U.S. Biovigilance Network. The U.S. Biovigilance Network is the first and only national collaboration between government and nongovernment agencies designed to confidentially track adverse reactions and incidents associated with blood collection and transfusion as well as tissue, organ and cell therapy transplantation. The Hemovigilance Module - focusing specifically on patients who receive blood and blood components -- is being developed within the Centers for Disease Control and Prevention's (CDC) National Healthcare Safety Network (NHSN), a patient safety surveillance system operated by the CDC's Division of Healthcare Quality Promotion.

"The U.S. is the only developed country that does not have an established method to track and monitor adverse events associated with blood transfusion on a national level," said AABB CEO Karen Shoos Lipton, JD. "We are pleased to be partnering with the U.S. Department of Health and Human Services, CDC and other private organizations to provide a forum that will enable us as a community to evaluate therapeutic protocols and make best practice recommendations to improve patient safety and reduce health care costs."

Though the U.S. blood supply is as safe as it has ever been, this country lacks a coordinated national network to track and monitor adverse events associated with the transfusion of blood and blood components. Fully reliable data about the relative risks of transfusion do not exist, particularly concerning life-threatening noninfectious hazards of transfusion such as transfusion of the wrong unit of blood into a patient and transfusion-related acute lung injury, or TRALI.

TRALI is just one of many examples of how mitigating the current adverse events associated with transfusions would produce large health care savings nationally and, most importantly, enhance patient safety. For patients at risk for TRALI, data collected and compiled from the Hemovigilance Module could lead to the development of new treatment protocols. In addition to improved care, an estimated $40 million or more could be saved by eliminating the need for further diagnostic patient assessments (including x-rays), respiratory treatment and extended hospital stays.

"The Hemovigilance Module in NHSN is an important step forward for blood safety in the United States," said Matthew J. Kuehnert, MD, FACP, director of the CDC's Office of Blood, Organ, and other Tissue Safety. "This unique collaborative effort between federal government and the private sector has great potential to be a critical building block for a national biovigilance program, which has as a common goal to improve patient safety and donor health."

For more information about the U.S. Biovigilance Network and the NHSN, please visit www.aabb.org/biovigilance and www.cdc.gov/nhsn/.

About AABB

Established in 1947, AABB (formerly known as the American Association of Blood Banks) is an international, not-for-profit association dedicated to the advancement of science and the practice of transfusion medicine and related biological therapies. The association is committed to improving health by developing and delivering standards, accreditation and educational programs and services to optimize patient and donor care and safety. AABB membership consists of approximately 1,800 institutions and 8,000 individuals, including physicians, scientists, administrators, medical technologists, nurses, researchers, blood donor recruiters and public relations personnel. Members are located in all 50 states and 80 countries.


'/>"/>
SOURCE AABB
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair
3. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
4. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
8. K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security
9. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
10. September is National Pain Awareness Month
11. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology:
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
Breaking Medicine News(10 mins):